Surveillance for hepatocellular carcinoma - current status and advances

Abstract

Aim: Hepatocellular carcinoma (HCC) is a common cancer worldwide, especially in Asia, with high mortality. Curative options are only available for early-stage HCC, which are usually asymptomatic and best diagnosed through surveillance. Risk factors associated with HCC include liver cirrhosis due to alcohol, chronic viral hepatitis infections and nonalcoholic steatohepatitis. We review the evidence supporting the benefits and drawbacks of HCC surveillance as well as new surveillance modalities.

Methods: A MEDLINE and Cochrane Database search with defined search phrases was performed. Studies published from Jan 2000 to Jul 2018 were reviewed and publications focusing on the benefits and harms of HCC surveillance were qualitatively synthesized. Modalities of HCC surveillance were also reviewed.

Results: A total of 5 randomized controlled trials (RCTs) and 24 cohort studies with sample size of more than 100 each were selected. Significant mortality reduction was demonstrated in 1 RCT. Cohort studies showed overall improved outcomes in the surveillance group with 61.3%-88% of HCC being detected in an early-stage and with up to 80% eligible for curative treatments. A quarter (27.5%) of the surveillance patients experienced additional scans or procedures due to false-positive results. Combination of ultrasound with alpha-fetoprotein increases HCC detection rate. Novel serum markers and liquid biopsy are attractive tools for surveillance as they are non-invasive and convenient.

Conclusion: The current evidence supports HCC surveillance as it detects earlier stage of tumor, allows more curative treatment and improves survival. Further research on hepatocarcinogenesis and novel surveillance modalities will continue to refine surveillance guidelines to reduce HCC-related mortality.

Keywords

Hepatocellular carcinoma / surveillance / surveillance modalities / screening / biomarkers

References

[1] Zhu RX,Lai CL.Epidemiology of hepatocellular carcinoma in the Asia-Pacific region..Gut Liver2016;10:332-9 PMCID:PMC4849684

[2] Schmidt S,Malek N,Greten TF.Critical appraisal of clinical practice guidelines for diagnosis and treatment of hepatocellular carcinoma..J Gastroenterol Hepatol2011;26:1779-86

[3] International Agency for Research on Cancer. GLOBOCAN 2012. Available from: http://globocan.iarc.fr/Default.aspx. [Last accessed on 9 Nov 2018]

[4] Mazzaferro V,Doci R,Pulvirenti A.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis..N Engl J Med1996;334:693-700

[5] Goh GBB,Tan CK.Changing epidemiology of hepatocellular carcinoma in Asia..Best Pract Res Clin Gastroenterol2015;29:919-28

[6] Goh GBB,Chang PE,Tan CK.Deciphering the epidemiology of hepatocellular carcinoma through the passage of time: a study of 1,401 patients across 3 decades..Hepatol Commun2017;1:564-71 PMCID:PMC5678902

[7] Heimbach JK,Finn RS,Abecassis MM.AASLD guidelines for the treatment of hepatocellular carcinoma..Hepatology2018;67:358-80

[8] Omata M,Kokudo N,Lee JM.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update..Hepatol Int2017;11:317-70 PMCID:PMC5491694

[9] Kudo M,Izumi N,Kadoya M.JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan..Liver Cancer2014;3:458-68 PMCID:PMC4531423

[10] Galle PR,Llovet JM,Piscaglia F.EASL clinical practice guidelines: management of hepatocellular carcinoma..J Hepatol2018;69:182-236

[11] Zhang BH,Tang ZY.Randomized controlled trial of screening for hepatocellular carcinoma..J Cancer Res Clin Oncol2004;130:417-22

[12] Chen JG,Chen QG,Shen QJ.Screening for liver cancer: results of a randomised controlled trial in Qidong, China..J Med Screen2003;10:204-9

[13] Trinchet JC,Bourcier V,Henrion J.Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities..Hepatology2011;54:1987-97

[14] Wang JH,Kee KM,Yen YH.Hepatocellular carcinoma surveillance at 4-vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community..Am J Gastroenterol2013;108:416-24

[15] Poustchi H,Strasser SI,Mccaughan GW.Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed?.Hepatology2011;54:1998-2004

[16] Taylor EJ,Guthrie JA.Modeling the benefits and harms of surveillance for hepatocellular carcinoma: information to support informed choices..Hepatology2017;66:1546-55

[17] Llovet JM,Lencioni R,Galle PR.EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma..J Hepatol2012;56:908-43

[18] Yu EW,Chen TH.Does screening or surveillance for primary hepatocellular carcinoma with ultrasonography improve the prognosis of patients?.Cancer J2004;10:317-25

[19] Nusbaum JD,Wright HC,Parpia T.The effect of hepatocellular carcinoma surveillance in an urban population with liver cirrhosis..J Clin Gastroenterol2015;49:e91-5

[20] Oeda S,Takasaki M,Otsuka T.Optimal follow-up of patients with viral hepatitis improves the detection of early-stage hepatocellular carcinoma and the prognosis of survival..Intern Med2016;55:2749-58 PMCID:PMC5088533

[21] Singal AG,Yerokun OA,Marrero JA.Hepatocellular carcinoma screening associated with early tumor detection and improved survival among patients with cirrhosis in the US..Am J Med2017;130:1099-106.e1

[22] Thein HH,Yeung LT,Yoshida EM.Improved survival in patients with viral hepatitis-induced hepatocellular carcinoma undergoing recommended abdominal ultrasound surveillance in Ontario: a population-based retrospective cohort study..PLoS One2015;10:1-18 PMCID:PMC4580446

[23] Wu CY,Ho HJ,Lee TY.Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study..Gut2016;65:693-701

[24] Trevisani F,Labate AMM,Rapaccini G.Surveillance for hepatocellular carcinoma in elderly italian patients with cirrhosis: effects on cancer staging and patient survival..Am J Gastroenterol2004;99:1470-6

[25] Trevisani F,Rapaccini G,Benvegnù L.Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience)..Am J Gastroenterol2002;97:734-44

[26] McMahon BJ,Harpster A,Lanier A.Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study..Hepatology2000;32:842-6

[27] Ungtrakul T,Chun-On P,Siripongsakun S.Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area..World J Gastroenterol2016;22:7806-12 PMCID:PMC5016381

[28] Yeh YP,Cho PY,Yen AM.Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan..Hepatology2014;59:1840-9 PMCID:PMC4296217

[29] Atiq O,Yopp AC,Marrero JA.An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis..Hepatology2016;65:1196-205 PMCID:PMC5659110

[30] Sarasin FP,Hadengue A.Cost-effectiveness of screening for detection of small hepatocellular carcinoma in Western patients with Child-Pugh class A cirrhosis..Am J Med1996;101:422-34

[31] Sherman M.Surveillance for hepatocellular carcinoma..Best Pract Res Clin Gastroenterol2014;28:783-93

[32] Yu SJ.A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016..Clin Mol Hepatol2016;22:7-17 PMCID:PMC4825164

[33] Tzartzeva K,Rich NE,Marrero JA.Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis..Gastroenterology2018;154:1706-18.e1 PMCID:PMC5927818

[34] Samoylova ML,Roberts JP.Predictors of ultrasound failure to detect hepatocellular carcinoma..Liver Transplant2018;24:1171-7

[35] Pocha C,McMaken KA,Thuras P.Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography - a randomised study..Aliment Pharmacol Ther2013;38:303-12

[36] Kim SY,Lim YS,Lee JY.MRI With liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma..JAMA Oncol2017;3:456 PMCID:PMC5470420

[37] Kumada T,Tada T,Tanikawa M.High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma..J Gastroenterol2014;49:555-63 PMCID:PMC3953543

[38] Marrero JA,Wang Y,Befeler AS.Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin- bound alpha-fetoprotein in early hepatocellular carcinoma..Gastroenterology2009;137:110-8 PMCID:PMC2704256

[39] Nakamura S,Sakaguchi K,Ohashi Y.Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size..Am J Gastroenterol2006;101:2038-43

[40] Ji J,Li Y,Yin Y.Diagnostic evaluation of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatitis B virus-related hepatocellular carcinoma in china: a large-scale, multicentre study..PLoS One2016;11:1-17 PMCID:PMC4829182

[41] Gentile I,Scotto R,Carriero C.Diagnostic accuracy of PIVKA-II, alpha-fetoprotein and a combination of both in diagnosis of hepatocellular carcinoma in patients affected by chronic HCV infection..In Vivo2017;31:695-700 PMCID:PMC5566924

[42] Liao W,Ge P,Xu H.Value of quantitative and qualitative analyses of circulating cell-free DNA as diagnostic tools for hepatocellular carcinoma..Medicine (Baltimore)2015;94:e722 PMCID:PMC4554041

[43] Zhou J,Yang XR.Liquid biopsy and its potential for management of hepatocellular carcinoma..J Gastrointest Cancer2016;47:157-67

[44] Li LM,Zhou ZX,Liu FY.Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma..Cancer Res2010;70:9798-807

[45] Hung CH,Lu SN,Chen CH.Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus..Int J Cancer2016;138:714-20

[46] Tat Trung N,Tong HV,Hoan PQ.Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma..PLoS One2018;13:1-17 PMCID:PMC5908085

[47] Motawi TK,El-Maraghy SA.Serum MicroRNAs as potential biomarkers for early diagnosis of hepatitis C virus-related hepatocellular carcinoma in egyptian patients..PLoS One2015;10:1-23 PMCID:PMC4564244

[48] Jepsen P,Andersen PK,Vilstrup H.Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study..Ann Intern Med2012;156:841-7W295

[49] Ascha MS,Lopez R,Feldstein AF.The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis..Hepatology2010;51:1972-8

[50] White D,El-Serag H.Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review..Clin Gastroenterol Hepatol2012;10:1342-59 PMCID:PMC3501546

[51] Mittal S,El-Serag HB,Duan Z.Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population..Clin Gastroenterol Hepatol2015;13:594-601.e1 PMCID:PMC4333060

[52] Mittal S.Epidemiology of hepatocellular carcinoma: consider the population..J Clin Gastroenterol.2013;47 Suppl:S2-6: PMCID:PMC3683119

[53] Fattovich G,Degos F,Diodati G.Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients..Gastroenterology1997;112:463-72

[54] Tsukuma H,Tanaka S,Yabuuchi T.Risk factors for hepatocellular carcinoma among patients with chronic liver disease..N Engl J Med1993;328:1797-801

[55] Jakobsen JC,Feinberg J,Fobian K.Direct-acting antivirals for chronic hepatitis C..Cochrane Database Syst Rev2017;9:CD012143

[56] Conti F,Scuteri A,Bolondi L.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals..J Hepatol2016;65:727-33

[57] Singh S,Loke YK.Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma: a systematic review and meta-analysis..Frontline Gastroenterol2018;9:262-70 PMCID:PMC6145438

[58] Singal AG,Tiro J.Early Detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis..PLoS Med2014;11:e1001624 PMCID:PMC3972088

[59] Kansagara D,Pasha AS,Freeman M.Screening for hepatocellular carcinoma in chronic liver disease: a systematic review..Ann Intern Med2014;161:261-9

[60] Yuen MF,Lauder IJ,Ooi CG.Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience..Hepatology2000;31:330-5

[61] Noda I,Nakahara H,Okimoto T.Regular surveillance by imaging for early detection and better prognosis of hepatocellular carcinoma in patients infected with hepatitis C virus..J Gastroenterol2010;45:105-12

[62] van Meer S,Coenraad MJ,van Nieuwkerk KM.Surveillance for hepatocellular carcinoma is associated with increased survival: results from a large cohort in the Netherlands..J Hepatol2015;63:1156-63

[63] Chaiteerakij R,Choi J,Thanapirom K.Surveillance for hepatocellular carcinoma reduces mortality: an inverse probability of treatment weighted analysis..Ann Hepatol2017;16:421-9

[64] Moher D,Tetzlaff J.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement..PLoS Med2009;6:e1000097 PMCID:PMC2707599

[65] Chiang JK,Kao YH.Effect of ultrasonography surveillance in patients with liver cancer: a population-based longitudinal study..BMJ Open2017;7:e015936 PMCID:PMC5541579

[66] Mittal S,Ying J,Sada YH.Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: a United States cohort..J Hepatol2016;65:1148-54 PMCID:PMC5322857

[67] Cucchetti A,Pecorelli A,Farinati F.Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma..J Hepatol2014;61:333-41

[68] El-Serag HB,Chen GJ,Richardson PA.Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA..Gut2011;60:992-7

[69] Stroffolini T,Pinzello G,Tommasini MA.Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance..Dig Liver Dis2011;43:875-80

[70] Yang JD,Slettedahl SW,Enders FT.Factors that affect risk for hepatocellular carcinoma and effects of surveillance..Clin Gastroenterol Hepatol2011;9:617-23

[71] Kuo YH,Chen CL,Lin CY.Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis..Eur J Cancer2010;46:744-51

[72] Pascual S,Zapater P,Sempere L.Usefulness of surveillance programmes for early diagnosis of hepatocellular carcinoma in clinical practice..Liver Int2008;28:682-9

[73] Tanaka H,Kobashi H,Nakamura S.Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival..Liver Int2006;26:543-51

[74] Toyoda H,Kiriyama S,Tanikawa M.Impact of surveillance on survival of patients with initial hepatocellular carcinoma: a study from Japan..Clin Gastroenterol Hepatol2006;4:1170-6

[75] Ando E,Tanaka M,Fukushima N.Surveillance program for early detection of hepatocellular carcinoma in Japan: results of specialized department of liver disease..J Clin Gastroenterol2006;40:942-8

[76] Chen THH,Yen MF,Sun CA.Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan..Int J Cancer2002;98:257-61